Homepage
Author:
CREATE Medicines, Inc.
Posted Date:
May 21, 2026
CREATE Medicines Strengthens Clinical and Scientific Advisory Board with Appointment of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD
CREATE Medicines, Inc.
May 21, 2026
CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology
CREATE Medicines, Inc.
May 21, 2026
CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors
CREATE Medicines, Inc.
April 23, 2026
CREATE Medicines to Showcase Multi-immune In Vivo CAR T, CAR NK, and All-RNA RetroT Platform at AACR 2026
CREATE Medicines, Inc.
April 17, 2026
